- Home
- OESX vs ABVC Comparison
OESX vs ABVC Comparison
Compare OESX & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OESX
- ABVC
- Stock Information
- Founded
- OESX 1996
- ABVC 2015
- Country
- OESX United States
- ABVC United States
- Employees
- OESX N/A
- ABVC N/A
- Industry
- OESX Building Products
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- OESX Consumer Discretionary
- ABVC Health Care
- Exchange
- OESX Nasdaq
- ABVC Nasdaq
- Market Cap
- OESX 19.3M
- ABVC 22.1M
- IPO Year
- OESX 2007
- ABVC N/A
- Fundamental
- Price
- OESX $0.60
- ABVC $2.31
- Analyst Decision
- OESX Strong Buy
- ABVC
- Analyst Count
- OESX 2
- ABVC 0
- Target Price
- OESX $1.75
- ABVC N/A
- AVG Volume (30 Days)
- OESX 135.4K
- ABVC 370.5K
- Earning Date
- OESX 06-26-2025
- ABVC 08-13-2025
- Dividend Yield
- OESX N/A
- ABVC N/A
- EPS Growth
- OESX N/A
- ABVC N/A
- EPS
- OESX N/A
- ABVC N/A
- Revenue
- OESX $79,720,000.00
- ABVC $508,383.00
- Revenue This Year
- OESX $19.97
- ABVC $735.18
- Revenue Next Year
- OESX $16.45
- ABVC N/A
- P/E Ratio
- OESX N/A
- ABVC N/A
- Revenue Growth
- OESX N/A
- ABVC 1904.43
- 52 Week Low
- OESX $0.56
- ABVC $0.40
- 52 Week High
- OESX $1.12
- ABVC $2.70
- Technical
- Relative Strength Index (RSI)
- OESX 45.72
- ABVC 64.81
- Support Level
- OESX $0.59
- ABVC $2.16
- Resistance Level
- OESX $0.61
- ABVC $2.70
- Average True Range (ATR)
- OESX 0.04
- ABVC 0.21
- MACD
- OESX 0.01
- ABVC 0.03
- Stochastic Oscillator
- OESX 31.54
- ABVC 67.41
About OESX Orion Energy Systems Inc.
Orion Energy Systems Inc is a developer, manufacturer, and seller of lighting and energy management systems. The company segments include Orion Lighting Segment, Orion Maintenance Segment and Orion Electric Vehicle Charging Segment. It derives maximum revenue from Lighting Segment.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.